Novel compound found effective against avian influenza virus

Feb 26, 2010

A novel compound is highly effective against the pathogenic H5N1 avian influenza virus, including some drug-resistant strains, according to new research led by a University of Wisconsin-Madison virologist.

The work, published in the Public Library of Science journal on Feb. 26, suggests that the compound CS-8958 is a promising alternative antiviral for prevention and treatment of bird flu.

are a primary countermeasure against human influenza viruses, including the highly pathogenic H5N1 avian influenza virus, which causes . Emerging strains resistant to existing drugs, particularly (Tamiflu), pose a threat and make the development of alternate antivirals a pressing public health issue, says Yoshihiro Kawaoka, a professor of pathobiological sciences at the UW-Madison School of Veterinary Medicine and senior author of the new study.

Kawaoka and a group of researchers from Japan, Vietnam, and Indonesia tested a novel neuraminidase inhibitor R-125489 and its prodrug CS-8958, which had previously shown potent activity against seasonal influenza viruses in laboratory animals.

Working with mice, the researchers found that a single intranasal dose of CS-8958 given two hours after infection with H5N1 influenza virus resulted in a higher survival rate and lower virus levels than a standard five-day course of oseltamivir. CS-8958 was also effective against highly pathogenic and oseltamivir-resistant strains of H5N1 virus.

In addition to its therapeutic use, CS-8958 also protected mice against lethal H5N1 infection when given seven days before infection with the virus.

"This compound requires only a single administration for both treatment and prophylaxis. Such prophylaxis would be highly desirable for seasonal influenza as well as a potential pandemic situation," says Kawaoka.

Although follow-up studies will be needed to confirm the applicability of the findings to humans, "CS-8958 is highly effective for the treatment and prophylaxis of infection with viruses, including oseltamivir-resistant mutants," the authors conclude.

Explore further: Second western Minnesota turkey farm hit by bird flu outbreak

More information: Kiso M, Kubo S, Ozawa M, Le QM, Nidom CA, et al. (2010) Efficacy of the New Neuraminidase Inhibitor CS-8958 against H5N1 Influenza Viruses. PLoS Pathog 6(2): e1000786. doi:10.1371/journal.ppat.1000786

add to favorites email to friend print save as pdf

Related Stories

Virus hybridization could create pandemic bird flu

Feb 22, 2010

Genetic interactions between avian H5N1 influenza and human seasonal influenza viruses have the potential to create hybrid strains combining the virulence of bird flu with the pandemic ability of H1N1, according to a new ...

Bird flu vaccine protects people and pets

Oct 20, 2008

A single vaccine could be used to protect chickens, cats and humans against deadly flu pandemics, according to an article published in the November issue of the Journal of General Virology. The vaccine protects birds and ma ...

Bird flu virus strain found in Maryland

Sep 12, 2006

U.S. scientists say an H5N1 avian influenza virus found earlier this month in Maryland is a low pathogenic subtype and poses no threat to humans.

Recommended for you

Nocturnal GERD tied to non-infectious rhinitis

15 hours ago

(HealthDay)—Nocturnal gastroesophageal reflux disease (GERD) appears to be a risk factor for non-infectious rhinitis (NIR), according to a study published online March 24 in Allergy.

COPD takes big toll on employment, mobility in US

19 hours ago

(HealthDay)—The respiratory illness known as COPD takes a toll on mobility and employment, with a new report finding that nearly one-quarter of Americans with the condition are unable to work.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.